Design, Development, and Optimization of Sterculia Gum-Based Tablet Coated with Chitosan/Eudragit RLPO Mixed Blend Polymers for Possible Colonic Drug Delivery

<table>Comparison of mean plasma drug concentration versus time profile curve after oral administration of MKT tablet (–), EC tablet (<svg height="7.9499998" id="M69" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 8.3125 7.9499998" width="8.3125" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,7.888)"><path d="M463 83l-4 -8h-436l-4 8l220 377h4zM381 121l-140 239l-140 -239h280z" id="x25B5"></path></g>
</svg>) and MCDDS (–) of AZA in rabbit.</table>

Journal of Pharmaceutics

fig7

Figure 7

Figure 7: Design, Development, and Optimization of Sterculia Gum-Based Tablet Coated with Chitosan/Eudragit RLPO Mixed Blend Polymers for Possible Colonic Drug Delivery 

Figure 7 | Design, Development, and Optimization of Sterculia Gum-Based Tablet Coated with Chitosan/Eudragit RLPO Mixed Blend Polymers for Possible Colonic Drug Delivery 